DeepMed Research

Ildong Pharmaceutical Co., Ltd.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-03-01

Employees: 1K

Market Cap: -

Website: http://www.ildong.com

Clinical Trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects

Phase 1

Recruiting

Conditions: Healthy Adult Subjects

Interventions: Drug: ID110521156
Drug: Placebo of 110521156

First Posted Date: 2024-10-10

Last Posted Date: 2024-12-24

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 36

Registration Number: NCT06635226

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Adult Subjects

Interventions: Drug: ID110521156
Drug: Placebo of ID110521156

First Posted Date: 2023-10-02

Last Posted Date: 2024-11-25

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 36

Registration Number: NCT06063291

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of ID120040002 in Healthy Volunteers

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: ID120040002
Drug: Compound-X
Drug: Placebo comparator

First Posted Date: 2022-12-23

Last Posted Date: 2022-12-23

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 86

Registration Number: NCT05663879

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

Phase 1

Terminated

Conditions: Healthy Participants

Interventions: Drug: Placebo
Drug: ID119031166M

First Posted Date: 2022-11-03

Last Posted Date: 2024-07-11

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 67

Registration Number: NCT05604287

Locations: 🇺🇸
California Clinical trials medical group/PAREXEL, Glendale, California, United States

To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers

Phase 1

Conditions: Dyslipidemias
Hypertension

Interventions: Combination Product: ID1803+ID1805
Combination Product: ID140009

First Posted Date: 2022-02-28

Last Posted Date: 2022-02-28

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 60

Registration Number: NCT05259020

Locations: 🇰🇷
H plus yangji hospital, Seoul, Korea, Republic of

IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics

Phase 1

Conditions: Type 2 Diabetes

Interventions: Drug: [Part 1.1] Placebo of IDG-16177
Drug: [Part 2] Placebo of IDG-16177
Drug: [Part 1.1] IDG-16177
Drug: [Part 2] IDG-16177
Drug: [Part1.2] IDG-16177
Drug: [Part 1.2] Placebo of IDG-16177
Drug: [Part 2] Sitagliptin

First Posted Date: 2021-07-29

Last Posted Date: 2022-08-11

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 94

Registration Number: NCT04982705

Locations: 🇩🇪
Parexel International GmbH Early Phase Clinical Unit Klinikum Westend, Berlin, Germany

Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function

Phase 1

Conditions: Renal Impairment

Interventions: Drug: Besifovir Dipivoxil Maleate

First Posted Date: 2020-01-31

Last Posted Date: 2020-01-31

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 40

Registration Number: NCT04249908

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean

Phase 3

Completed

Conditions: Acute Migraine

Interventions: Drug: Lasmiditan 100mg
Drug: Placebo
Drug: Lasmiditan 50mg

First Posted Date: 2020-01-06

Last Posted Date: 2021-04-01

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 294

Registration Number: NCT04218162

Locations: 🇰🇷
IlDong Pharmaceutical Co Ltd, Seoul, Korea, Republic of

Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate

Phase 4

Conditions: Tenofovir Disoproxil Fumarate
Besifovir Dipivoxil Maleate
Hepatitis B

Interventions: Drug: Tenofovir disoproxil fumarate(TDF)
Drug: Besifovir Dipivoxil Maleate

First Posted Date: 2019-12-17

Last Posted Date: 2019-12-17

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 152

Registration Number: NCT04202536

Locations: 🇰🇷
Korea University Medical Center, Ansan, Kyounggi-do, Korea, Republic of

To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults

Phase 1

Conditions: Dyslipidemias
Hypertension

Interventions: Combination Product: ID1803
Combination Product: ID1803+ID1801
Combination Product: ID1801

First Posted Date: 2019-12-04

Last Posted Date: 2019-12-26

Lead Sponsor: IlDong Pharmaceutical Co Ltd

Target Recruit Count: 30

Registration Number: NCT04185090

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy